<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523754</url>
  </required_header>
  <id_info>
    <org_study_id>Vaginal nitric oxide donor</org_study_id>
    <nct_id>NCT03523754</nct_id>
  </id_info>
  <brief_title>Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor</brief_title>
  <official_title>Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dina Yahia Mansour</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety &amp; efficacy of nitric oxide donors such as intravaginal isosorbide&#xD;
      mononitrate in addition to misoprostol Versus misoprostol only for the whole process of&#xD;
      induction of labor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Type of Study: Randomised controlled clinical trial.&#xD;
&#xD;
        -  Study Setting: This study will be conducted at Ain Shams University's Emergency&#xD;
           department of the Maternal Hospital.&#xD;
&#xD;
        -  Study Period: From January 2018 to June 2018 (6 months)&#xD;
&#xD;
        -  Randomization: Will be done using computer generated randomization sheet using MedCalcÂ©&#xD;
           version 13. ( Appendix 1)&#xD;
&#xD;
        -  Allocation and concealment: Fifty opaque envelops will be numbered serially and in each&#xD;
           envelope the corresponding letter which denotes the allocated group will be put&#xD;
           according to randomization table. Then all envelopes will be closed and put in one box.&#xD;
           When the first patient arrives, the first envelope will be opened and the patient will&#xD;
           be allocated according to the letter inside.&#xD;
&#xD;
        -  Study Population: Fifty pregnant women.&#xD;
&#xD;
             -  Inclusion Criteria:&#xD;
&#xD;
                  -  Primigravida.&#xD;
&#xD;
                  -  From 20 to 30 years old.&#xD;
&#xD;
                  -  Singleton term (between 40 to 42 weeks of gestation).&#xD;
&#xD;
                  -  Good general condition with straightforward enthusiasm for the trial.&#xD;
&#xD;
             -  Exclusion Criteria:&#xD;
&#xD;
                  -  IUGR.&#xD;
&#xD;
                  -  Rupture of membranes.&#xD;
&#xD;
                  -  Favorable cervix (Bishop score : '8' or more)&#xD;
&#xD;
                  -  Cephalopelvic disproportion,fetal malpresentation.&#xD;
&#xD;
                  -  Antepartum hemorrhage, any abnormal placentation such as placenta previa,&#xD;
                     morbidly adherent placenta.&#xD;
&#xD;
                  -  Uterine fibroid.&#xD;
&#xD;
                  -  Previous uterine major surgery such as : myomectomy.&#xD;
&#xD;
                  -  Any medical disorder such as : gestational diabetes, diabetes mellitus,&#xD;
                     hypertension, preeclampsia, coagulation disorders, renal and hepatic&#xD;
                     dysfunction.&#xD;
&#xD;
        -  Sampling Method: Convenience sampling.&#xD;
&#xD;
        -  Sample Size: Fifty women.&#xD;
&#xD;
        -  Sample Justification: Using data from previous study by Abdellah et al. 2010, which&#xD;
           compared isosorbide mononitrate and misoprostol versus misprostol only. Misoprostol only&#xD;
           group induction to delivery interval was 23 hours while in the isosorbide mononitrate&#xD;
           and misorprostol group it was 19.6 hours. We will use sample size of 25 women in each of&#xD;
           the two groups to achieve 91% power to detect statistical difference of atleast 3.4&#xD;
           hours. With estimated group standard deviations of 4.0 and 2.6 and with a significance&#xD;
           level (alpha) of 0.05 using Mann-Whitney test; the sample size of 50 women as stated&#xD;
           before is satisfactory to detect difference between initial dose to delivery.&#xD;
&#xD;
        -  Ethical Considerations: An informed consent will be taken from all participants, it will&#xD;
           be in Arabic language and confirmed by date &amp; time. No harm will be inflicted &amp; no&#xD;
           benefit will be deprived in this study.&#xD;
&#xD;
        -  Study Procedures:&#xD;
&#xD;
             -  Fifty Primigravida women will be recruited according to inclusion and exclusion&#xD;
                criteria.&#xD;
&#xD;
             -  History taking.&#xD;
&#xD;
             -  Physical examination.&#xD;
&#xD;
             -  Ultrasound: for placental localization excluding abnormal localization, exclude&#xD;
                Fetal IUGR, oligohydraminos, polyhydraminos, fibroids.&#xD;
&#xD;
             -  Laboratory investigations: CBC (complete blood count) , Coagulation Profile, Liver&#xD;
                function test, Kidney function test, ABO Rhesus D (RhD).&#xD;
&#xD;
             -  Counseling of the patient about isosorbide mononitrate and misoprostol.&#xD;
&#xD;
             -  Recruited patients will fill a written consent.&#xD;
&#xD;
             -  Two types of envelopes will be available, one with misoprostol &amp; placebo, other&#xD;
                will contain misoprostol &amp; isosorbide mononitrate which will be given by vaginal&#xD;
                route.&#xD;
&#xD;
             -  Patient will choose an envelope from the previous 2 types.&#xD;
&#xD;
             -  2 groups will be formed; group 1 will take both misoprostol &amp; isosorbide&#xD;
                mononitrate, group 2 will take Misoprostol only. Group 1 will take intial dose of&#xD;
                40mg isosorbide mononitrate (Mono-Mak) in the posterior vaginal fornix which will&#xD;
                not be repeated; followed by intravaginal 25mcg of misoprostol (Vagiprost),&#xD;
                misoprostol will be repeated every 6 hours for maximum of 5 doses (i.e. 125mcg),&#xD;
                (FIGO recommendation for misoprostol regimen 2017 &amp; WHO recommendations for&#xD;
                induction of labour 2011). Misoprostol will be stopped when labour is established&#xD;
                defined by 3 contractions every 10 minuites, each contraction of 30 seconds&#xD;
                duration, with amplitude of 40 mmHg or if 6 hours passed after the last misoprostol&#xD;
                dose and labour is not established as defined before with unfavorable cervix&#xD;
                defined by bishop score of 6 or less, cesarean delivery will be performed. Group 2&#xD;
                will take only misoprostol with same scheme for misoprostol as before in group 1.&#xD;
&#xD;
             -  Induction of labor process will take place, during which:&#xD;
&#xD;
                  -  Maternal blood pressure &amp; pulse will be assessed every 30 minutes for the&#xD;
                     first 2 hours then hourly after that; temperature will be assessed every 4&#xD;
                     hours.&#xD;
&#xD;
                  -  Fetal auscultation will be carried out every 15 minutes in 1st stage of labor,&#xD;
                     every 5 minutes in 2nd stage of labor after uterine contraction for at least 1&#xD;
                     minuite.&#xD;
&#xD;
                  -  CTG will be performed every 2 hours or if there are concerns during fetal&#xD;
                     ausculatation. Continuous CTG maybe continued upon maternal request or if&#xD;
                     there are high risk factors such as contractions that last longer than 60&#xD;
                     seconds(hypertonus) or more than 5 contractions in 10 minutes(tachysystole),&#xD;
                     Oxytocin use.&#xD;
&#xD;
        -  Study Interventions: Cesarean Delivery will be performed in the following circumstances:&#xD;
&#xD;
             -  if Induction of labor failure is established defined by unfavorable cervix after 6&#xD;
                hours from the last dose of 5 doses of Misoprostol each is 25 mcg (maximum dose of&#xD;
                125mcg)&#xD;
&#xD;
             -  If management of protraction &amp; arrest disorders failed.&#xD;
&#xD;
             -  If CTG monitoring was classified as pathological and conservative management&#xD;
                failed; or if CTG monitoring warned the need for urgent intervention.&#xD;
&#xD;
        -  Statistical Analysis: Descriptive statistics for measured variables will be expressed as&#xD;
           range mean and standard deviation (for metric data); range, median and interquartile&#xD;
           range (for discrete data); and number and proportion (for categorical data). Demographic&#xD;
           data and primary and secondary outcomes of all women will be compared using t-test (for&#xD;
           quantitative parametric measures), Mann-Whitney's U-test (for quantitative&#xD;
           non-parametric measures) and chi squared and Fisher's Exact tests (for categorical&#xD;
           measures). Pearson's correlation coefficient (for metric variables) and Spearman's&#xD;
           correlation coefficient (for rank variables) will be used to estimate association&#xD;
           between variables.&#xD;
&#xD;
        -  Statistical Package: Data will be collected, edited and entered into suitable software&#xD;
           for data entry &amp; analysis such as 'SPSS version 20'.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Primigravida.&#xD;
From 20 to 30 years old.&#xD;
Singleton term (between 40 to 42 weeks of gestation).&#xD;
Good general condition with straightforward enthusiasm for the trial.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease interval between drug use to delivery</measure>
    <time_frame>6 months</time_frame>
    <description>Adding Isosorbide Mononitrate to Misoprostol will decrease time required for induction of labor.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Induction of Labor</condition>
  <arm_group>
    <arm_group_label>Misoprostol only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will receive Intravaginal Misoprostol only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isosorbide Mononitrate &amp; Misoprostol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This group will reveive intravaginal Isosorbide Mononitrate &amp; Misoprostol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate 40 MG to study group</intervention_name>
    <description>Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening &amp; induction of labor in study group</description>
    <arm_group_label>Isosorbide Mononitrate &amp; Misoprostol</arm_group_label>
    <arm_group_label>Misoprostol only</arm_group_label>
    <other_name>Misoprostol 25Mcg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primigravida.&#xD;
&#xD;
          -  From 20 to 30 years old.&#xD;
&#xD;
          -  Singleton term (between 40 to 42 weeks of gestation).&#xD;
&#xD;
          -  Good general condition with straightforward enthusiasm for the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  IUGR.&#xD;
&#xD;
          -  Rupture of membranes.&#xD;
&#xD;
          -  Favorable cervix (Bishop score : '8' or more)&#xD;
&#xD;
          -  Cephalopelvic disproportion,fetal malpresentation.&#xD;
&#xD;
          -  Antepartum hemorrhage, any abnormal placentation such as placenta previa, accreta,&#xD;
             increta and percreta&#xD;
&#xD;
          -  Uterine fibroid.&#xD;
&#xD;
          -  Previous uterine major surgery such as : myomectomy, uterine repair caused by trauma&#xD;
             and metroplasty for Mullerian anomalies.&#xD;
&#xD;
          -  Any medical disorder such as : gestational diabetes, diabetes mellitus, hypertension,&#xD;
             preeclampsia, renal &amp; hepatic dysfunction, coagulation disorders.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women only.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hesham M. Harb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Obstetrics &amp; Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dina Y. Mansour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Obstetrics &amp; Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yahia M. A. Mohamed ELBoukhary A.A., M.B.B.Ch</last_name>
    <role>Principal Investigator</role>
    <affiliation>Msc Student, Resident of Obstetrics &amp; Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obs &amp; Gyn,Faculty of Medicine, Ain shams University.</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dina Yahia Mansour</investigator_full_name>
    <investigator_title>Lecturer of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>Induction of labor</keyword>
  <keyword>isosorbide mononitrate</keyword>
  <keyword>misoprostol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We will see if the study may add new to the scientific society or no, if the study is done, completed in a good environment and we are convinced that it may provide new information to others, we will share it.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

